Source: Annual Congress 2002 - COPD - general -3
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Corkovic, N. Kostic, D. Begovic, L. Nagorni-Obradovic, S. Ignjatovic (Belgrade, Kragujevac, Yugoslavia). Vitamin C, VIP (vasoactive intestinal polypeptide) and gastrin in the serum of COPD patients in stable state and during exacerbation. Eur Respir J 2002; 20: Suppl. 38, 1665

Member's Comments

No comment yet.

Related content which might interest you: VIP (vasoactive intestinal polypeptide) and vitamin C in the serum of COPD patients before and after therapy Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006 Serum level of VIP (vasoactive intestinal polypeptide) in patients with COPD in stable state and during exacerbation Source: Eur Respir J 2001; 18: Suppl. 33, 483s Year: 2001 Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis Source: Eur Respir J 2004; 24: 958-963 Year: 2004 Concentration of vasoactive intestinal peptide (VIP) and substance P (SP) in bronchi of patients with mild to moderate bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005 Vasoactive intestinal peptide receptor 2 (VIPR2) in central airways of smokers Source: Eur Respir J 2002; 20: Suppl. 38, 88s Year: 2002 Distribution of vasoactive intestinal peptide( VIP)- and substance P (SP)- containing innervation in bronchi of patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004 Vasoactive intestinal peptide (VIP) for treatment of COPD: improvement in spiroergometry and 6 minute walking distance Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 Circulating vasoactive intestinal peptide for diagnosis of exacerbation of COPD Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Sputum Vitamin D binding protein (VDBP) GC1S/1S genotype predicts airway obstruction: a prospective study in smokers with COPD Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Inhaled vasoactive intestinal peptide (VIP) improves pulmonary gas exchange in acute respiratory distress syndrome (ARDS) - a case report Source: Eur Respir J 2003; 22: Suppl. 45, 70s Year: 2003 Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Vitamin D and cathelicidin serum levels in children with infection induced asthma Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Serum surfactant protein D (SP-D) is a lung derived biomarker for COPD that is responsive to treatment with oral corticosteroids Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 Serum vitamin D levels and exercise-induced bronchoconstriction in children with asthma Source: Eur Respir J 2011; 37: 1366-1370 Year: 2011 Serum leptin and neuropeptide Y levels in asthmatic and cystic fibrosis children Source: Eur Respir J 2003; 22: Suppl. 45, 400s Year: 2003 Serum surfactant protein D (SPD) as a specific marker for COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Inhaled vasoactive intestinal peptide exerts immune-regulatory effects in patients with sarcoidosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009 Increased total serum levels of ghrelin and nesfatin in chronic obstructive pulmonary disease Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015